Browse by author
Lookup NU author(s): Dr Emma Kampouraki,
Dr Peter Avery,
Dr Tina Biss,
Professor Farhad Kamali
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2017 Wiley Periodicals, Inc. Vitamin K is essential, for the activation of clotting proteins, as well as the biosynthesis of osteocalcin in bones and the activation of matrix-Gla protein needed in maintaining vasculature health. Cytochrome p450 4F2 (CYP4F2) enzyme is involved in vitamin K catabolism. Genetic polymorphism in CYP4F2 is thus likely to affect vitamin K systemic availability. We show that children on chronic warfarin therapy have low levels of vitamin K and vitamin K levels are linked to CYP4F2 genotype. Long-term low levels of vitamin K, influenced by CYP4F2 genotype, might affect bone development and vascular health in children on chronic warfarin therapy.
Author(s): Kampouraki E, Avery PJ, Biss T, Kamali F
Publication type: Article
Publication status: Published
Journal: Pediatric Blood and Cancer
Print publication date: 01/12/2017
Online publication date: 18/05/2017
Acceptance date: 03/05/2017
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017
Publisher: John Wiley and Sons Inc.
Altmetrics provided by Altmetric